Thematic Units



Index > 7VCC > Heart Failure
Imprimir sólo la columna central

Aldosterone Blockade and Heart Failure

Bertram Pitt

University of Michigan School of Medicine.
Michigan, United States of America.

Lecture with audio and slides
The following should be available:
Flash Player (click here to download it free of charge), speakers or headphones,
and preferably use Firefox, Chrome or Internet Explorer.
If pop up blockers are installed, they should be deactivated.

Access to the Lecture

Curriculum of Dr. Bertram Pitt

- Graduate of the Medical School of the University of Basel (Switzerland).
- He is Professor of Internal Medicine, University of Michigan School of Medicine. Before that, he spent 15 years as the Director, Division of Cardiology, University of Michigan School of Medicine.
- His research is in practically all areas of cardiovascular disease, with special emphasis on the ischemic heart disease and heart failure.
- He is author of close to 500 papers and chapters in books and is Member of the Editorial Board on a number of Journals in cardiovascular diseases.
- He received his postdoctoral training at Beth Israel Hospital Boston and the Johns Hopkins Hospital University, and then joined the Faculty of the John Hopkins University.
- He joined the University of Michigan in 1977 as the Professor of Internal Medicine and Director of the Division of Cardiology.
- Member of numerous professional societies and has held office in several of them. Among others, he was Chairman, Council on Circulation of the American Heart Association, President of the Michigan Chapter of American College of Cardiology, Chairman, Young Investigator’s Award Committee of the American College of Cardiology, and is currently Chairman of the Reveal Committee of the ACC.
- Has distinguished himself as the Principal or Co-principal Investigator of a number of clinical trials, such as the Digitalis-Captopril Trial (300 patients), Studies of Left Ventricular Dysfunction (SOLVD - 6,700 patients), Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC Study - 600 patients), QUIET Study (1,750 patients), Prevent Trial (600 patients), Reflect II Trial (300 patients), RALES trial (3,200 patients), Ephesus (6,400 patients) and ELITE II (3,000 patients).
- He has been consulting companies like Warner Lambert Company, Beecham Pharmaceuticals, Nova Pharmaceuticals, Gensia Pharmaceuticals, Centocor Pharmaceuticals, Boots Pharmaceuticals, Ivax Pharmaceuticals, Pharmacia, Merck, Novartis, Takeda, Bristol Myers Squibb, and others.





Publication: October 2011

Your questions, contributions and commentaries will be answered
by the lecturer or experts on the subject in the Heart Failure list.
Please fill in de form and Press the "Send" button.
See message: September - October - November

November 30th., 2011

Question, contribution or
Name and Surname:
E-Mail address:
Re-type Email address:



Declared to be of National Interest
National Presidency,

National Ministry of Health
Argentina - Res. 200/11

Tobacco-free Congress